Skip to main content
EJNMMI Research

Table 3 All new observed hematological and biochemical toxicity after [166Ho]-radioembolization during 1 year of follow-up

From: Inflammatory markers and long term hematotoxicity of holmium-166-radioembolization in liver-dominant metastatic neuroendocrine tumors after initial peptide receptor radionuclide therapy

 

CTCAE grade

Baseline (Pre-[166Ho]-radioembolization)a

0–12 months post-[166Ho]-radioembolization

End of follow-up (1 year)b

1–2

3

4

1–2

3

4

1–2

3

4

Thrombocyte

8/30

  

9/31

  

2/26

  

Neutrophil

   

5/31

  

2/26

  

Lymphocyte

10/27

5/27

 

7/31

9/31

1/31

1/26

1/26

 

Leukocyte

10/30

  

11/31

  

5/26

  

Hemoglobin

6/30

  

8/31

1/31

 

4/26

  
  1. Values are n/available observed patients with the maximum observed toxicity grade during the designated period of follow-up. CTCAE grades at pre-[166Ho]-radioembolization were counted when the grade was higher than at pre-PRRT, CTCAE grades in post-[166Ho]-radioembolization follow-up were counted when the grade was higher than at baseline
  2. aSeveral values not available due to missing data at pre-PRRT
  3. bFive patients did not reach the 12-month follow-up
Back to article page